메뉴 건너뛰기




Volumn 48, Issue 12, 2009, Pages 1537-1540

Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial - Results from the scleroderma lung study

Author keywords

Lung disease; Mahler's Dyspnoea Index; Minimal clinically important differences; Minimally important differences; Scleroderma; Scleroderma Lung Study

Indexed keywords

CYCLOPHOSPHAMIDE; PLACEBO;

EID: 75649084837     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep284     Document Type: Article
Times cited : (41)

References (15)
  • 1
    • 33745227399 scopus 로고    scopus 로고
    • Cyclophosphamide versus placebo in scleroderma lung disease
    • Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
    • (2006) N Engl J Med , vol.354 , pp. 2655-2666
    • Tashkin, D.P.1    Elashoff, R.2    Clements, P.J.3
  • 2
    • 0021256105 scopus 로고
    • The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes
    • Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8.
    • (1984) Chest , vol.85 , pp. 751-758
    • Mahler, D.A.1    Weinberg, D.H.2    Wells, C.K.3    Feinstein, A.R.4
  • 3
    • 34248589179 scopus 로고    scopus 로고
    • Impact of oral cyclophosphamide on healthrelated quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study
    • Khanna D, Yan X, Tashkin DP et al. Impact of oral cyclophosphamide on healthrelated quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 2007;56:1676-84.
    • (2007) Arthritis Rheum , vol.56 , pp. 1676-1684
    • Khanna, D.1    Yan, X.2    Tashkin, D.P.3
  • 4
    • 13444252280 scopus 로고    scopus 로고
    • Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the Scleroderma Lung Study
    • Khanna D, Clements PJ, Furst DE et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005;52:592-600.
    • (2005) Arthritis Rheum , vol.52 , pp. 592-600
    • Khanna, D.1    Clements, P.J.2    Furst, D.E.3
  • 5
    • 0024852022 scopus 로고
    • Measurement of health status. Ascertaining the minimal clinically important difference
    • Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.
    • (1989) Control Clin Trials , vol.10 , pp. 407-415
    • Jaeschke, R.1    Singer, J.2    Guyatt, G.H.3
  • 6
    • 0018887574 scopus 로고    scopus 로고
    • Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis scleroderma, Arthritis Rheum 1980;23:581-90
    • Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
  • 7
    • 34547408278 scopus 로고    scopus 로고
    • Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis
    • Khanna D, Furst DE, Wong WK et al. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res 2007;16: 1083-92.
    • (2007) Qual Life Res , vol.16 , pp. 1083-1092
    • Khanna, D.1    Furst, D.E.2    Wong, W.K.3
  • 8
    • 33750367940 scopus 로고    scopus 로고
    • Minimally important difference in diffuse systemic sclerosis- results from the D-Penicillamine Study
    • Khanna D, Furst DE, Hays RD et al. Minimally important difference in diffuse systemic sclerosis- results from the D-Penicillamine Study. Ann Rheum Dis 2006; 65:1325-9.
    • (2006) Ann Rheum Dis , vol.65 , pp. 1325-1329
    • Khanna, D.1    Furst, D.E.2    Hays, R.D.3
  • 9
    • 33846952106 scopus 로고    scopus 로고
    • Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis
    • Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol 2007;34:280-9.
    • (2007) J Rheumatol , vol.34 , pp. 280-289
    • Wells, G.1    Li, T.2    Maxwell, L.3    Maclean, R.4    Tugwell, P.5
  • 10
    • 0037368520 scopus 로고    scopus 로고
    • Meaningful effect size and patterns of response of the transition dyspnea index
    • Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003;56:248-55.
    • (2003) J Clin Epidemiol , vol.56 , pp. 248-255
    • Witek Jr, T.J.1    Mahler, D.A.2
  • 11
    • 40649117704 scopus 로고    scopus 로고
    • Outcomes for COPD pharmacological trials: From lung function to biomarkers
    • Cazzola M, MacNee W, Martinez FJ et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69.
    • (2008) Eur Respir J , vol.31 , pp. 416-469
    • Cazzola, M.1    MacNee, W.2    Martinez, F.J.3
  • 12
    • 20144382504 scopus 로고    scopus 로고
    • Approaches and recommendations for estimating minimally important differences for health-related quality of life measures
    • Hays RD, Farivar S, Liu H. Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD 2005;2:63-7.
    • (2005) COPD , vol.2 , pp. 63-67
    • Hays, R.D.1    Farivar, S.2    Liu, H.3
  • 13
    • 37549004786 scopus 로고    scopus 로고
    • Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes
    • Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008;61:102-9.
    • (2008) J Clin Epidemiol , vol.61 , pp. 102-109
    • Revicki, D.1    Hays, R.D.2    Cella, D.3    Sloan, J.4
  • 14
    • 57349181492 scopus 로고    scopus 로고
    • The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice
    • Khanna D, Pope JE, Khanna PP et al. The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice. J Rheumatol 2008;35:2339-43.
    • (2008) J Rheumatol , vol.35 , pp. 2339-2343
    • Khanna, D.1    Pope, J.E.2    Khanna, P.P.3
  • 15
    • 42449112005 scopus 로고    scopus 로고
    • Development of a provisional core set of response measures for clinical trials of systemic sclerosis
    • Khanna D, Lovell DJ, Giannini E et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008; 67:703-9.
    • (2008) Ann Rheum Dis , vol.67 , pp. 703-709
    • Khanna, D.1    Lovell, D.J.2    Giannini, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.